Principal Financial Group Inc. Purchases 78,198 Shares of Progyny, Inc. $PGNY

Principal Financial Group Inc. raised its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 16.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 554,916 shares of the company’s stock after buying an additional 78,198 shares during the period. Principal Financial Group Inc.’s holdings in Progyny were worth $9,422,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of PGNY. Fifth Third Bancorp raised its holdings in shares of Progyny by 8,354.1% in the first quarter. Fifth Third Bancorp now owns 58,249 shares of the company’s stock worth $989,000 after buying an additional 57,560 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. boosted its holdings in Progyny by 141.9% during the 1st quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 170,076 shares of the company’s stock valued at $2,888,000 after acquiring an additional 99,764 shares during the period. Strs Ohio grew its position in Progyny by 25.3% in the 1st quarter. Strs Ohio now owns 41,600 shares of the company’s stock valued at $706,000 after acquiring an additional 8,400 shares during the last quarter. Fort Washington Investment Advisors Inc. OH increased its stake in Progyny by 46.9% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after purchasing an additional 859,289 shares during the period. Finally, Pictet Asset Management Holding SA increased its stake in Progyny by 16.4% in the first quarter. Pictet Asset Management Holding SA now owns 13,799 shares of the company’s stock worth $234,000 after purchasing an additional 1,943 shares during the period. Institutional investors own 94.93% of the company’s stock.

Insider Activity at Progyny

In other Progyny news, CFO Mark S. Livingston sold 2,517 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $25.50, for a total transaction of $64,183.50. Following the completion of the sale, the chief financial officer directly owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. This represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of Progyny stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the transaction, the insider directly owned 59,117 shares in the company, valued at approximately $1,512,212.86. The trade was a 2.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 36,916 shares of company stock valued at $939,875 over the last 90 days. Company insiders own 9.90% of the company’s stock.

Analyst Upgrades and Downgrades

PGNY has been the topic of a number of research analyst reports. Barclays upped their price target on shares of Progyny from $23.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Bank of America boosted their price objective on shares of Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. Canaccord Genuity Group raised their target price on shares of Progyny from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. BTIG Research boosted their price target on Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a report on Friday. Finally, KeyCorp increased their price objective on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Progyny presently has an average rating of “Moderate Buy” and an average target price of $32.67.

Progyny Stock Performance

NASDAQ:PGNY opened at $31.19 on Friday. The firm has a 50-day simple moving average of $27.90 and a 200-day simple moving average of $23.11. Progyny, Inc. has a one year low of $16.10 and a one year high of $33.06. The firm has a market cap of $2.44 billion, a P/E ratio of 40.51, a P/E/G ratio of 2.47 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.24. The company had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. Progyny’s revenue was down 26.4% compared to the same quarter last year. During the same period last year, the company posted $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, research analysts predict that Progyny, Inc. will post 1.19 EPS for the current fiscal year.

Progyny declared that its Board of Directors has authorized a stock buyback program on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.